| Assessment Status | Rapid Review Complete |
| HTA ID | 22011 |
| Drug | Trifluridine/tipiracil |
| Brand | Lonsurf® |
| Indication | As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. |
| Assessment Process | |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that trifluridine/tipiracil not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
